Tocilizumab in uveitis refractory to other biologic drugs: A study of 3 cases and a literature review

Clinical and Experimental Rheumatology

Volumn 32, Issue , 2014, Pages S54-S57

  Calvo Río, Vanesa ^a   de la Hera, David ^a   Beltrán Catalán, Emma ^b   Blanco, Ricardo ^a   Hernández, Marisa ^b   Martínez Costa, Lucía ^c   Loricera, Javier ^a   Cañal, Joaquín ^a   Ventosa, Juan ^a   Ortiz Sanjuán, Francisco ^a   Pina, Trinitario ^a   González Vela, M Carmen ^a   Rodríguez Cundín, Paz ^a   González Gay, Miguel A ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^c Hospital Universitario Doctor Peset de Valencia   (Spain)

Author keywords

Anti TNF agent; Beh et; Immune mediated diseases; Tocilizumab; Uveitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; GOLIMUMAB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BEHCET DISEASE; CASE REPORT; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EYE INFLAMMATION; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; OUTCOME ASSESSMENT; RETINA MACULA CYSTOID EDEMA; RHEUMATOID ARTHRITIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UVEITIS; VISUAL ACUITY; DRUG RESISTANCE; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TREATMENT OUTCOME; UVEITIS;

EID: 84907483775     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. CHANG JH, WAKEFIELD D: Uveitis: a global perspective. Ocul Immunol Inflamm 2002; 10: 263-79.
2. DíAZ-LLOPIS M, SALOM D, GARCIA-DE-VICUñA C et al.: Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 2012; 119: 1575-81.
3. SMIT RL, BAARSMA GS: Epidemiology of uveitis. Curr Opin Ophthalmol 1995; 6: 57-61.
4. ARIDA A, FRAGIADAKI K, GIAVRI E, SFIKAKIS PP: Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum 2011; 41: 61-70.
5. SOBRIN L, KIM EC, CHRISTEN W, PAPADAKI T, LETKO E, FOSTER CS: Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 2007; 125: 895-900.
6. SHARMA SM, NESTEL AR, LEE RWJ et al.: Clinical review: anti-TNF alpha therapies in uveitis: perspective on 5 years of clinical experience. Ocul Immunol Inflamm 2009: 17: 403-14.
7. PEREZ VL, PAPALIODIS GN, CHU D, ANZAAR F, CHRISTEN W, FOSTER CS: Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies. Ocul Immunol Inflamm 2004; 12: 193-201.
8. TANAKA T, OGATA A, NARAZAKI M: Tocilizumab for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 2010; 6: 843-54.
9. TANAKA T, NARAZAKI M, KISHIMOTO T: Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett 2011; 585: 3699-709.
10. YOSHIMURA T, SONODA K-H, OHGURO N et al.: Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology 2009; 48: 347-54.
11. ISHIHARA K, HIRANO T: IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002; 13: 357-68.
12. DESCHENES J, MURRAY PI, RAO NA, NUSSENBLATT RB: International Uveitis Study Group (IUSG) clinical classification of uveitis. Ocul Immunol Inflamm 2008; 16: 1-2.
13. HIRANO T, OHGURO N, HOHKI S et al.: A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol 2012; 22: 298-302.
14. MUSELIER A, BIELEFELD P, BIDOT S, VINIT J, BESANCENOT JF, BRON A: Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm 2011; 19: 382-3.
15. TAPPEINER C, HEINZ C, GANSER G, HEILIGENHAUS A: Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol 2012; 39: 1294-5.
16. OSHITARI T, KAJITA F, TOBE A et al.: Refractory uveitis in patient with castleman disease successfully treated with tocilizumab. Case Rep Ophthalmol Med 2012; 2012: 968180.
17. ADáN A, MESQUIDA M, LLORENç V et al.: Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol 2013; 251: 2627-32.
18. HOHKI S, OHGURO N, HARUTA H et al.:Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses. Exp Eye Res 2010; 91: 162-70.
19. HARUTA H, OHGURO N, FUJIMOTO M et al.: Blockade of interleukin-6 signaling suppresses not only Th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis. Invest Opthalmol Vis Sci 2011; 52: 3264-71.